LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

LLY

715.06

-1.34%↓

JNJ

152.52

-0.44%↓

ABBV

182.34

+0.35%↑

NVO

68.13

-0.07%↓

UNH

296.46

-2.25%↓

Search

Roivant Sciences Ltd

Abierto

SectorSanidad

10.94 0.46

Resumen

Variación precio

24h

Actual

Mínimo

10.83

Máximo

10.96

Métricas clave

By Trading Economics

Ingresos

212M

25M

Ventas

4.5M

9M

BPA

-0.199

Margen de beneficios

280.018

Empleados

908

EBITDA

-52M

-274M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+63.04% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

7.7B

Apertura anterior

10.48

Cierre anterior

10.94

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

187 / 382 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Weak Bullish Evidence

Roivant Sciences Ltd Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

21 may 2025, 23:25 UTC

Acciones populares

Stocks to Watch: Navitas Semiconductor, Urban Outfitters, Lumen Technologies, LiveRamp

21 may 2025, 21:57 UTC

Adquisiciones, fusiones, absorciones

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75 Billion -- Update

21 may 2025, 21:29 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefónica's Operations in Uruguay

21 may 2025, 21:01 UTC

Principales Movimientos del Mercado

Nvidia Selects Navitas Semiconductor to Work on Next-Generation 800V HVDC Architecture

21 may 2025, 23:49 UTC

Charlas de Mercado

Gold Edges Higher on Possible Investor Shift Away From Government Bonds -- Market Talk

21 may 2025, 23:37 UTC

Charlas de Mercado

Nikkei May Fall, Tracking Wall Street's Losses -- Market Talk

21 may 2025, 23:33 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Iluzanebart Return to Licensor Amgen to Occur Prior to Closing of Sanofi Deal

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience Sees Sanofi Deal Strengthening Development Path for Oral Small Molecule TREM2 Agonist Program

21 may 2025, 23:32 UTC

Adquisiciones, fusiones, absorciones

Vigil Neuroscience: Shareholders to Get Up to $10 a Share in Sanofi Deal >SAN.FR VIGL

21 may 2025, 23:32 UTC

Charlas de Mercado
Adquisiciones, fusiones, absorciones

James Hardie's Weak Update Spurs Questions Before AZEK Vote -- Market Talk

21 may 2025, 23:31 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics: Remaining Entity to Focus on Contract Development & Manufacturing Organization Business

21 may 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics: Spun-Off Entity Tentatively Named Samsung Episholdings

21 may 2025, 23:30 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics: Separated Business Entity to Focus on R&D Affiliate Samsungbioepis, New Investment

21 may 2025, 23:29 UTC

Adquisiciones, fusiones, absorciones

Samsung Biologics to Spin off R&D Segment Into Separate Holdings Company

21 may 2025, 23:28 UTC

Ganancias

Singtel to Finance Buybacks Via Excess Capital Generated From Asset Recycling >Z74.SG

21 may 2025, 23:27 UTC

Ganancias

Singtel Sets Up S$2.0B Share-Buyback Program >Z74.SG

21 may 2025, 23:26 UTC

Ganancias

Singtel: Net Rose Due to Exceptional Gain From Partial Divestment of Comcentre Headquarters >Z74.SG

21 may 2025, 23:26 UTC

Ganancias

Singtel FY25 Rev S$14.15B Vs. S$14.13B >Z74.SG

21 may 2025, 23:26 UTC

Ganancias

Singtel FY25 Net S$4.02B Vs. Net S$795.0M >Z74.SG

21 may 2025, 23:23 UTC

Adquisiciones, fusiones, absorciones

Sanofi: VGL101, Vigil's Second Molecule Program, Isn't Being Acquired

21 may 2025, 23:22 UTC

Principales Noticias

Walmart to Cut 1,500 Corporate Jobs in Restructuring -- WSJ

21 may 2025, 23:22 UTC

Adquisiciones, fusiones, absorciones

Sanofi Sees No Effect From Vigil Deal on 2025 Outlook >SAN.FR

21 may 2025, 23:20 UTC

Adquisiciones, fusiones, absorciones

Sanofi: Vigil Deal Enhances Early-Stage Pipeline, Includes VG-3927, Which Will Be Evaluated in Alzheimer's Disease Study

21 may 2025, 23:18 UTC

Adquisiciones, fusiones, absorciones

Sanofi to Buy Vigil Neuroscience for $8 a Share at Closing >SAN.FR VIGL

21 may 2025, 23:04 UTC

Principales Noticias

EV Owners Face Annual Fee Under Proposed Tax Bill -- Barrons.com

21 may 2025, 21:46 UTC

Principales Noticias

NBCUniversal Bids for MLB Rights That Were Dropped by ESPN -- WSJ

21 may 2025, 21:42 UTC

Principales Noticias
Adquisiciones, fusiones, absorciones

AT&T to Buy Lumen's Mass Markets Fiber Business for $5.75B -- Update

21 may 2025, 21:14 UTC

Adquisiciones, fusiones, absorciones

Millicom to Acquire Telefónica's Ops in Uruguay

21 may 2025, 21:07 UTC

Principales Noticias

NBCUniversal Bids for Major League Baseball Rights ESPN Dropped, Sources Say -- WSJ

21 may 2025, 21:06 UTC

Adquisiciones, fusiones, absorciones

Uber Stock Is Dropping. Blame Elon Musk and Tesla. -- Barrons.com

Comparación entre iguales

Cambio de precio

Roivant Sciences Ltd previsión

Precio Objetivo

By TipRanks

63.04% repunte

Estimación a 12 Meses

Media 18 USD  63.04%

Máximo 18 USD

Mínimo 18 USD

De acuerdo con 5 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Roivant Sciences Ltd Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

5 ratings

5

Comprar

0

Mantener

0

Vender

Puntuación técnica

By Trading Central

11 / 11.18Soporte y Resistencia

Corto Plazo

Weak Bullish Evidence

Medio plazo

Bullish Evidence

Largo Plazo

Bearish Evidence

Sentimiento

By Acuity

187 / 382 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Roivant Sciences Ltd

Roivant Sciences Ltd., a commercial-stage biopharmaceutical company, engages in the development and commercialization of medicines for inflammation and immunology areas. The company provides Vants, a model to develop and commercialize its medicines and technologies focusing on biopharmaceutical businesses, discovery-stage companies, and health technology startups. It offers VTAMA, a novel topical approved for the treatment of psoriasis and in development for the treatment of atopic dermatitis; IMVT-1402 and batoclimab, which are fully human monoclonal antibodies that targets the neonatal Fc receptor in development across various IgG-mediated autoimmune indications; brepocitinib, a potent small molecule inhibitor of TYK2 and JAK1 in development for the treatment of dermatomyositis and non-infectious uveitis, as well as for other therapies in various stages of clinical development; and Namilumab, a fully human anti-GM-CSF monoclonal antibody under Phase 2 clinical trial for the treatment of inflammatory and autoimmune diseases. The company also provides delivery platforms comprising lipid nanoparticle platform and ligand conjugate platform. It has collaboration and license agreements with Boehringer Ingelheim International, GmbH for conducting discovery work on RNA-specific adenosine deaminase 1 targeting and modulating compounds; and with Japan Tobacco Inc. for the rights to develop, register, and market tapinarof in Japan for the treatment of psoriasis and atopic dermatitis. The company was founded in 2014 and is based in London, the United Kingdom.